Company Description

Granza Bio is developing cancer therapeutics modelled from our body’s own immune system. Our therapeutics termed “attack particles” are engineered to specifically target only cancer cells, preventing any unwanted toxicity and adverse side effects. Our attack particles have shown cancer-killing efficacy in brain (glioblastoma), ovarian, lung, and skin cancers. Our platform can also be deployed to target a great range of diseases including autoimmune diseases and infections. Interested to know more? Get in touch founders@granzabio.com!